Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Girgis RE, et al. Among authors: oudiz rj. Ann Rheum Dis. 2007 Nov;66(11):1467-72. doi: 10.1136/ard.2007.069609. Epub 2007 May 1. Ann Rheum Dis. 2007. PMID: 17472992 Free PMC article. Clinical Trial.
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ; Treprostinil Study Group. Simonneau G, et al. Among authors: oudiz r. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4. doi: 10.1164/ajrccm.165.6.2106079. Am J Respir Crit Care Med. 2002. PMID: 11897647 Clinical Trial.
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Solèr M. Langleben D, et al. Among authors: oudiz r. Am Heart J. 2002 May;143(5):E4. doi: 10.1067/mhj.2002.121806. Am Heart J. 2002. PMID: 12040360 Clinical Trial.
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group. McLaughlin VV, et al. Among authors: oudiz rj. J Cardiovasc Pharmacol. 2003 Feb;41(2):293-9. doi: 10.1097/00005344-200302000-00019. J Cardiovasc Pharmacol. 2003. PMID: 12548091 Clinical Trial.
Beraprost therapy for pulmonary arterial hypertension.
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group. Barst RJ, et al. Among authors: oudiz r. J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25. doi: 10.1016/s0735-1097(03)00463-7. J Am Coll Cardiol. 2003. PMID: 12821234 Free article. Clinical Trial.
Sitaxsentan therapy for pulmonary arterial hypertension.
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR; STRIDE-1 Study Group. Barst RJ, et al. Among authors: oudiz r. Am J Respir Crit Care Med. 2004 Feb 15;169(4):441-7. doi: 10.1164/rccm.200307-957OC. Epub 2003 Nov 20. Am J Respir Crit Care Med. 2004. PMID: 14630619 Clinical Trial.
128 results